Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
:MLYS
RESEARCH TOOLSreports
MLYS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.24 - $18.38
Previous CloseN/A
Volume137.34K
Average Volume (3M)1.87M
Market Cap
$790.84M
Enterprise Value$416.79M
Total Cash (Recent Filing)$114.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.59
Next Earnings
May 19, 2025EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding64,876,230
10 Day Avg. Volume1,661,708
30 Day Avg. Volume1,873,290
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.17
Forecast
1Y Price Target
$36.50Price Target Upside172.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive outcomes from the Advance-HTN and Launch-HTN pivotal trials along with consistent KOL support.
Drug EfficacyLorundrostat demonstrated a significant reduction in systolic blood pressure, which was particularly impressive to experts at the conference.
Bears Say
Market ChallengesThe heavily genericized hypertension market means that marketing and payer-related challenges are anticipated for Mineralys Therapeutics.
Market CompetitionA smaller company like Mineralys Therapeutics may face challenges competing against larger companies, indicating a need for partnership to succeed commercially.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $8.24 and its highest was $18.38 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Mineralys Therapeutics, Inc.’s market cap is $790.84M.
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is May 19, 2025 which is in 36 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on Feb 12, 2025. The company reported -$0.98 earnings per share for the quarter, beating the consensus estimate of -$1.077 by $0.097.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -0.98.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 64,876,230 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$0.98 in its last earnings report, beating expectations of -$1.077. Following the earnings report the stock price went up 10.041%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MLYS
---
Mineralys Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.50 (172.39% Upside)
$36.50 (172.39% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 12.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $33.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 34.8%
Last 30 Days ▲ 34.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.21%
12-Months-Change
Fundamentals
Return on Equity
-82.24%
Trailing 12-Months
Asset Growth
-18.17%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
---
MLYS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a positive outlook overall with strong clinical progress and a solid financial position, despite increased R&D expenses and net loss. The company remains optimistic about upcoming data readouts and market potential for lorundrostat.Read More>---
MLYS Stock 12 Month Forecast
Average Price Target
$36.50
▲(172.39% Upside)
Technical Analysis
Best Analysts Covering MLYS
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+12.80%
reiterated a buy rating 14 days ago
Copying Rami Katkhuda's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +12.80% per trade.
---